Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade
Yuying Jiang, Yongbing Yang, Yingchao Hu, Rui Yang, Jiajia Huang, Yi Liu, Yuqing Wu, Sheng Li, Chunmei Ma, Fiachra Humphries, Bingwei Wang, Xi Wang, Zhibin Hu, Shuo Yang
Abstract
T cell activation in a cGAS-dependent manner. Moreover, pharmacological inhibition of GSDMD-mediated pyroptosis and PD-L1 improve anti-tumor immunity, highlighting the potential of combining GSDMD/PD-L1 inhibition for immunotherapy as a therapeutic strategy.
Topics & Concepts
PyroptosisImmunotherapyImmune checkpointImmune systemImmunityTumor microenvironmentAcquired immune systemCancer researchBlockadeInnate immune systemBiologyImmunologyInflammasomeInflammationReceptorBiochemistryInflammasome and immune disordersImmune Cell Function and InteractionIL-33, ST2, and ILC Pathways